FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Divis Gregory J				2. Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC AVDL						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) C/O AVADEL PHARMACEUTICALS PLC 10 EARLSFORT TERRACE					3. Date of Earliest Transaction (Month/Day/Year) 12/07/2021							X Officer (give title Other (specify below)  Chief Executive Officer				
(Street)  DUBLIN  (City)			D02 T380 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)					6. In Line						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2. Transac Date (Month/Da	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			5. Amoun Securities Beneficia Owned Fo Reported	s F lly ( ollowing (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)		(111511.4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution or Exercise (Month/Day/Year) if any		3A. Deemed Execution Da if any (Month/Day/Y	ate, Transaction Code (Instr.		n Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	11(3)	
Stock Option (Right to Buy)	\$8.2	12/07/2021		A		310,000		(1)	12	2/07/2031	ADSs <sup>(2)</sup>	310,000	\$0	310,000	D	

## Explanation of Responses:

- 1. Options become exercisable as to 77,500 ADSs on each of the first four anniversaries after the 12/07/2021 grant date.
- 2. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

/s/ Jerad Seurer, as Attorney-in-Fact 12/09/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.